FDA to Review Genentech’s Avastin as Front-line Treatment for Advanced Ovarian Cancer

FDA to Review Genentech’s Avastin as Front-line Treatment for Advanced Ovarian Cancer
The U.S. Food and Drug Administration has accepted for review Genentech‘s supplemental Biologics License Application (sBLA) seeking the approval of Avastin (bevacizumab) in combination with chemotherapy, as a front-line treatment for women with advanced ovarian cancer. The FDA’s decision is expected by June 25, 2018. Front-line treatment in ovarian cancer is the first treatment a woman receives

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *